Eilean Therapeutics Unveils ZE74-0282 at ASH 2025
Slice of Healthcare Team
11/07/2025
Key highlights
- First-in-class JAK2 inhibitor targeting V617F mutation.
- Initiating clinical studies in December 2025.
- Selective inhibition of mutant JAK2 while sparing wild-type.
- Promising preclinical data showing superior efficacy.
- Potential disease-modifying therapy for myeloproliferative disorders.
Source: PR Newswire
Notable Quote
“ ZE74-0282 represents a significant advancement in the treatment of JAK2 V617F-driven myeloproliferative disorders. ”
Amy Burd, PhD, Chief Scientific Officer at Eilean Therapeutics LLC
Why this matters
The introduction of ZE74-0282 marks a pivotal moment in the treatment landscape for myeloproliferative neoplasms, offering a targeted approach that preserves normal hematopoiesis while effectively addressing the JAK2 V617F mutation. This development is particularly significant for the healthcare sector.
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
